Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

Blood Cancer J. 2015 Aug 7;5(8):e334. doi: 10.1038/bcj.2015.62.

Authors

S Z Usmani¹, R Sexton², S Ailawadhi³, J J Shah⁴, J Valent⁵, M Rosenzweig⁶, B Lipe⁷, J A Zonder⁸, S Fredette⁹, B Durie¹⁰, A Hoering², B Bartlett¹¹, R Z Orlowski⁴

Affiliations

¹ Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, USA.
² Cancer Research and Biostatistics, Seattle, WA, USA.
³ Mayo Clinic, Jacksonville, FL, USA.
⁴ MD Anderson Cancer Center, Houston, TX, USA.
⁵ Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁶ City of Hope, Los Angeles, CA, USA.
⁷ University of Kansas Cancer Center, Westwood, KS, USA.
⁸ Karmanos Cancer Institute, Detroit, MI, USA.
⁹ SWOG Operations, San Antonio, TX, USA.
¹⁰ Cedar-Sinai Medical Center, Los Angeles, CA, USA.
¹¹ Bristol-Myers Squibb, Princeton, NJ, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Clinical Trials, Phase I as Topic
Dexamethasone / administration & dosage
Humans
Induction Chemotherapy
Lenalidomide
Multiple Myeloma / drug therapy*
Randomized Controlled Trials as Topic
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
elotuzumab
Thalidomide
Bortezomib
Dexamethasone
Lenalidomide

Grants and funding